St. Luke's Episcopal Hospital to Add CyberKnife System to Treatment Offerings

SUNNYVALE, Calif., July 24 /PRNewswire-FirstCall/ -- Accuray Incorporated (Nasdaq: ARAY), a global leader in the field of radiosurgery, today announced that St. Luke's Episcopal Hospital in Houston has purchased a CyberKnife(R) Robotic Radiosurgery System to further expand treatment offerings for its nationally recognized NeuroScience Center program. The CyberKnife System will be installed in a newly constructed facility designed to expand the hospital's radiation oncology facility.

St. Luke's has been ranked by U.S. News & World Report as one of the nation's top 50 hospitals for a number of specialties, including neurology and neurosurgery. It is the only hospital in Houston, and only one of four hospitals in Texas, to be named a Neuroscience Center of Excellence by NeuStrategy, Inc.

"The addition of the CyberKnife System to our tools will further strengthen our position as a provider of innovative, comprehensive and high quality care," said Youssef G. Comair, M.D., FRCSC at St. Luke's. "When we surveyed our physicians about what new technology was needed to serve our community, they overwhelmingly believed that the CyberKnife System was the best option for our patient population. The CyberKnife System is truly a revolutionary device that will enable us to give patients a non-surgical alternative for treatment of cancer or other conditions affecting the nervous system."

St. Luke's will use the CyberKnife System primarily to treat vascular malformations and intracranial tumors, but it will give the hospital flexibility to treat tumors in the spine, lung, prostate, kidney and pancreas as well. Because the CyberKnife System combines robotics and sophisticated real-time imaging technology, it is capable of delivering high doses of radiation to tumors anywhere in the body with sub-millimeter accuracy. These capabilities eliminate the need for invasive head and body frames, which other systems require to immobilize the patient for tumor tracking. The robotic arm also enables the system to target tumors that are unreachable by other radiosurgery systems or surgery. As a result, the CyberKnife System offers new hope to patients who are considered inoperable, have surgically complex tumors, or are seeking an alternative to surgery.

"St. Luke's is renowned for its commitment to the highest standards of neurological and neurosurgical patient care," said Euan S. Thomson, Ph.D., president and CEO of Accuray. "We are pleased to be working with them to offer their patients a non-invasive alternative to brain surgery and other cancer treatments."

About the CyberKnife(R) Robotic Radiosurgery System

The CyberKnife Robotic Radiosurgery System is the world's only robotic radiosurgery system designed to treat tumors anywhere in the body non-invasively. Using continual image guidance technology and computer controlled robotic mobility, the CyberKnife System automatically tracks, detects and corrects for tumor and patient movement in real-time throughout the treatment. This enables the CyberKnife System to deliver high-dose radiation with pinpoint precision, which minimizes damage to surrounding healthy tissue and eliminates the need for invasive head or body stabilization frames.

About Accuray

Accuray Incorporated (Nasdaq: ARAY), based in Sunnyvale, Calif., is a global leader in the field of radiosurgery dedicated to providing an improved quality of life and a non-surgical treatment option for those diagnosed with cancer. Accuray develops and markets the CyberKnife Robotic Radiosurgery System, which extends the benefits of radiosurgery to include extracranial tumors, including those in the spine, lung, prostate, liver and pancreas. To date, the CyberKnife System has been used to treat more than 40,000 patients worldwide and currently more than 130 systems have been installed in leading hospitals in the Americas, Europe and Asia. For more information, please visit www.accuray.com.

Safe Harbor Statement

The foregoing may contain certain forward-looking statements that involve risks and uncertainties, including uncertainties associated with the medical device industry. Except for the historical information contained herein, the matters set forth in this press release, clinical studies, regulatory review and approval, and market acceptance and commercialization of products and services are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements speak only as of the date the statements are made and are based on information available at the time those statements are made and/or management's good faith belief as of that time with respect to future events. You should not put undue reliance on any forward-looking statements. Important factors that could cause actual performance and results to differ materially from the forward-looking statements we make include: market acceptance of products; competing products, the combination of our products with complementary technology; and other risks detailed from time to time under the heading "Risk Factors" in our report on Form 10-K for the 2007 fiscal year, as updated from time to time by our quarterly reports on Form 10- Q and our other filings with the Securities and Exchange Commission. The Company's actual results of operations may differ significantly from those contemplated by such forward-looking statements as a result of these and other factors. We assume no obligation to update forward-looking statements to reflect actual performance or results, changes in assumptions or changes in other factors affecting forward-looking information, except to the extent required by applicable securities laws.

SOURCE Accuray Incorporated
07/24/2008
CONTACT: Susan Lehman, Rockpoint Public Relations, +1-510-832-6006,
susan@rockpointpr.com; Stephanie Tomei, Public Relations Manager,
+1-408-789-4234, stomei@accuray.com, both for Accuray Incorporated
Web site: http://www.accuray.com